UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse

Frontiers in oncology, 2022-02, Vol.12, p.802648-802648

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7030-7030

2022

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7005-7005

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7051-TPS7051

2021

Link zum Volltext

Verfügbarkeit prüfen

Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't"

JAMA : the journal of the American Medical Association, 2003-08, Vol.290 (6), p.806

2003

Link zum Volltext

Verfügbarkeit prüfen

The impact of infection on health-related quality of life (HRQoL) in patients with Philadelphia negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph- R/R BCP ALL) in a randomized, open-label, phase 3 study (TOWER)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18511-e18511

2019

Link zum Volltext

Verfügbarkeit prüfen

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.7508-7508

2020

Link zum Volltext

Verfügbarkeit prüfen

Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.7536-7536

2020

Link zum Volltext

Verfügbarkeit prüfen

Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7011-7011

2019

Link zum Volltext

Verfügbarkeit prüfen

Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7028-7028

2019

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7044-7044

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7042-7042

2018

Link zum Volltext

Verfügbarkeit prüfen

Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19528-e19528

2020

Link zum Volltext

Verfügbarkeit prüfen

Superior therapy response predictions for patients with acute myeloid leukemia (AML) using Cellworks Singula: MyCare-009-01

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19502-e19502

2020

Link zum Volltext

Verfügbarkeit prüfen

Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from a randomized phase III study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7032-7032

2017

Link zum Volltext

Verfügbarkeit prüfen

ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S266-S266

2021

Link zum Volltext

Verfügbarkeit prüfen

Poster: ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S209-S209

2021

Link zum Volltext

Verfügbarkeit prüfen

Enasidenib in mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7004-7004

2017

Link zum Volltext

Verfügbarkeit prüfen

A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS7096-TPS7096

2015

Link zum Volltext

Verfügbarkeit prüfen

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Blood, 2015-12, Vol.126 (23), p.679-679

2015

Link zum Volltext

Verfügbarkeit prüfen

Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Blood, 2015-12, Vol.126 (23), p.861-861

2015

Link zum Volltext

Verfügbarkeit prüfen

Space Geodetic Observations of Nazca-South America Convergence Across the Central Andes

Science (American Association for the Advancement of Science), 1998-01, Vol.279 (5349), p.358-362

1998

Link zum Volltext

Verfügbarkeit prüfen

Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7043-7043

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)
Reviews
(1)

Sprache

Englisch
(50)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(5)
Life Sciences & Biomedicine
(3)
Andes
(2)
Biological And Medical Sciences
(2)
Central Andes
(2)
Crustal Shortening
(2)
Earth Sciences
(2)
Earth, Ocean, Space
(2)
Exact Sciences And Technology
(2)
Geology
(2)
Global Positioning System
(2)
Humans
(2)
Internal Geophysics
(2)
Male
(2)
Medical Sciences
(2)
Nazca Plate
(2)
Peru
(2)
Satellite Methods
(2)
Solid-Earth Geophysics
(2)
Solid-Earth Geophysics, Tectonophysics, Gravimetry
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

823O Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)

Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse

Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia

A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't"

The impact of infection on health-related quality of life (HRQoL) in patients with Philadelphia negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph- R/R BCP ALL) in a randomized, open-label, phase 3 study (TOWER)

P494: A FIRST‐IN‐HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK‐MYELODYSPLASIA

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML)

Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML

Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)

Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study

Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT)

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML)

Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02

Superior therapy response predictions for patients with acute myeloid leukemia (AML) using Cellworks Singula: MyCare-009-01

Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from a randomized phase III study

ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Poster: ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Enasidenib in mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study

A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131)

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Treatment with Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Space Geodetic Observations of Nazca-South America Convergence Across the Central Andes

Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies

Suchergebnisse filtern